{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(7)"],"submitter":["Pu L"],"pubmed_abstract":["<h4>Background</h4>Y-box binding protein 1 (YB-1) overexpression has been shown in various tumor cells including hepatocellular carcinoma (HCC); moreover, this protein can be actively secreted.<h4>Objectives</h4>The aim of this study was to establish a method to quantify serum YB-1 and evaluate its clinical application in the clinical diagnosis of HCC.<h4>Patients and methods</h4>Recombinant YB-1 and two populations of its antibodies were prepared. A monoclonal antibody was specific to the N-terminus of YB-1 amino acids 134-160; and another was a polyclonal antibody. A sandwich-type chemiluminescence immunoassay (CLIA) was developed and evaluated. Levels of YB-1 and alpha fetoprotein (AFP) in serum samples from 105 HCC patients, 25 hepatitis B virus patients, 25 cirrhosis patients, and 50 "],"journal":["Hepatitis monthly"],"pagination":["e8918"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3782250"],"repository":["biostudies-literature"],"pubmed_title":["Development of a Chemiluminescence Immunoassay for Serum YB-1 and its Clinical Application as a Potential Diagnostic Marker for Hepatocellular Carcinoma."],"pmcid":["PMC3782250"],"pubmed_authors":["Ping L","Chenggui L","Qindong L","Yu L","Zhiguang T","Jing S","Qin W","Qianfeng X","Feng C","Jinyu D","Bianqin G","Wenbin K","Pu L"],"additional_accession":[]},"is_claimable":false,"name":"Development of a Chemiluminescence Immunoassay for Serum YB-1 and its Clinical Application as a Potential Diagnostic Marker for Hepatocellular Carcinoma.","description":"<h4>Background</h4>Y-box binding protein 1 (YB-1) overexpression has been shown in various tumor cells including hepatocellular carcinoma (HCC); moreover, this protein can be actively secreted.<h4>Objectives</h4>The aim of this study was to establish a method to quantify serum YB-1 and evaluate its clinical application in the clinical diagnosis of HCC.<h4>Patients and methods</h4>Recombinant YB-1 and two populations of its antibodies were prepared. A monoclonal antibody was specific to the N-terminus of YB-1 amino acids 134-160; and another was a polyclonal antibody. A sandwich-type chemiluminescence immunoassay (CLIA) was developed and evaluated. Levels of YB-1 and alpha fetoprotein (AFP) in serum samples from 105 HCC patients, 25 hepatitis B virus patients, 25 cirrhosis patients, and 50 ","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013","modification":"2025-04-26T21:52:12.303Z","creation":"2019-03-27T01:16:29Z"},"accession":"S-EPMC3782250","cross_references":{"pubmed":["24069038"],"doi":["10.5812/hepatmon.8918"]}}